Background: Removal of anti-ABO is an important component of the preconditioning regimen for ABO-incompatible (ABOi) renal transplant. Cascade plasmapheresis (CP) is one of the extracorporeal methods of antibody removal, others being conventional plasma exchange (PE) and immunoadsorption. There is no previous published experience with CP in this context. The purpose of this study was to present an early experience with this approach.
Study Design And Methods: Consecutive ABOi renal transplant recipients in whom CP was used for pre- and posttransplant anti-ABO removal were included. All the patients received intravenous rituximab 2 weeks before transplant. After 1 week, CP was started along with oral tacrolimus and mycophenolate sodium. Alternate-day CP was done to attain immediate pretransplant antibody titer of not more than 8.
Results: Fifteen ABOi renal transplant recipients had baseline (pretreatment) antibody titers ranging from 16 to 512. Desensitization rate was 100%. The mean number of procedures before transplant to achieve titer of not more than 8 was 3.27 ± 1.39. Patient survival was 93% and death-censored graft survival was 87%. Biopsy-proven acute rejection was seen in three patients (20%), one (6.67%) being acute antibody mediated rejection. The complication rate during CP was 4% and two patients had bleeding complication after surgery. Posttransplant infection rate was 13%.
Conclusion: Based on limited number of patients, we conclude that CP is a safe and effective extracorporeal method for pretransplant ABO antibody removal in patients undergoing ABOi transplant. Patients undergoing CP met target preoperative antibody titers and the clinical outcomes were acceptable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.13427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of ABO-incompatible kidney transplants with very high isoagglutinin titers: a single-center experience and literature review.
Front Immunol
December 2024
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.
Background: ABO-incompatible kidney transplantation (ABOi-KTx) represents a possible solution to address the shortage of kidney donors. However, these transplants present immunological challenges, particularly when isoagglutinin titers are elevated pretransplant.
Methods: Single-center retrospective study describing clinical and biological outcomes of 8 patients who underwent ABOi-KTx with initial isoagglutinin titers ≥ 1/512.
The Burden of ABO-Incompatible Kidney Transplantation: Readmission Rates and Complications, a Twenty-Year Analysis.
J Clin Med
December 2024
Department of Visceral Surgery and Transplantation, University Hospital Zurich, 8091 Zurich, Switzerland.
: ABO-incompatible live-donor kidney transplantation (ABOi-LDKT) has become an established treatment for end-stage renal disease. Non-inferiority in the long-term graft function compared to ABO-compatible live-donor kidney transplantations (ABOc-LDKTs) has been shown. However, the assumed burden due to complications owing to increased immunosuppression inherent to ABOi-LDKTs has not yet been quantified.
View Article and Find Full Text PDFA comparative study on outcomes of ABO-incompatible kidney transplants between robot-assisted vs. open surgery-propensity score-matched analysis: a retrospective cohort study.
BMC Nephrol
November 2024
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Article Synopsis
- Robot-assisted kidney transplantation (RAKT) is gaining popularity, but there's limited research on its effectiveness for immunologically high-risk patients, particularly those with ABO incompatibility (ABOi), compared to traditional open kidney transplantation (OKT).
- A study involving 239 living-donor transplants compared 210 ABOi-OKT cases with 29 ABOi-RAKT cases, using statistical methods to ensure valid comparisons and analyze outcomes like acute rejection and graft failure.
- Results showed similar one- and two-year survival rates and kidney function between RAKT and OKT, but RAKT had longer surgery times and cold ischemic periods, while hospital stays were shorter for RAKT, indicating it is a safe and effective
Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.
Front Immunol
November 2024
Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
Article Synopsis
- ABO-incompatible kidney transplantation (KT) is increasingly used to address organ shortages, but high levels of anti-ABO antibodies can hinder successful transplantation despite existing desensitization methods.
- Eculizumab was used as an additional treatment to help patients with very high anti-ABO antibodies who did not respond to standard therapies, showing improvements in kidney function and antibody levels after transplant.
- The study indicates that short-term eculizumab treatment may effectively support ABOi KT patients by maintaining stable kidney function and reducing antibody levels, even in cases previously deemed challenging.
C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.
Transpl Int
October 2024
Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.
Article Synopsis
- The study investigates the risk factors for acute antibody-mediated rejection (ABMR) in ABO blood group incompatible kidney transplants (ABO-I), focusing on donor and recipient samples.
- Researchers analyzed A/B antigen expression in kidney tissues and other blood components from 104 donors and assessed pre-transplant recipient serum samples for antibody levels.
- They found that while A/B antigen levels in donors did not correlate with ABMR incidence, higher C1q-IgG binding ability in recipients was linked to an increased risk of ABMR, suggesting it may serve as a predictive indicator.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!